Hide metadata

dc.date.accessioned2024-01-22T13:28:15Z
dc.date.available2024-01-22T13:28:15Z
dc.date.created2023-04-26T14:37:36Z
dc.date.issued2023
dc.identifier.citationOender, Demet Faber, Jennifer Wilke, Carlo Schaprian, Tamara Lakghomi, Asadeh Mengel, David Schöls, Ludger Traschütz, Andreas Fleszar, Zofia Dufke, Claudia Vielhaber, Stefan Machts, Judith Giordano, Ilaria Grobe-Einsler, Marcus Klopstock, Thomas Stendel, Claudia Boesch, Sylvia Nachbauer, Wolfgang Timmann-Braun, Dagmar Thieme, Andreas Gustafsson Kamm, Christoph Dudesek, Ales Tallaksen, Chantal Marie Elisabeth Wedding, Iselin Marie Filla, Alessandro Schmid, Matthias Synofzik, Matthis Klockgether, Thomas . Evolution of Clinical Outcome Measures and Biomarkers in Sporadic Adult-Onset Degenerative Ataxia. Movement Disorders. 2023, 654-664
dc.identifier.urihttp://hdl.handle.net/10852/107142
dc.description.abstractABSTRACT Background Sporadic adult‐onset ataxias without known genetic or acquired cause are subdivided into multiple system atrophy of cerebellar type (MSA‐C) and sporadic adult‐onset ataxia of unknown etiology (SAOA). Objectives To study the differential evolution of both conditions including plasma neurofilament light chain (NfL) levels and magnetic resonance imaging (MRI) markers. Methods SPORTAX is a prospective registry of sporadic ataxia patients with an onset >40 years. Scale for the Assessment and Rating of Ataxia was the primary outcome measure. In subgroups, blood samples were taken and MRIs performed. Plasma NfL was measured via a single molecule assay. Regional brain volumes were automatically measured. To assess signal changes, we defined the pons and middle cerebellar peduncle abnormality score (PMAS). Using mixed‐effects models, we analyzed changes on a time scale starting with ataxia onset. Results Of 404 patients without genetic diagnosis, 130 met criteria of probable MSA‐C at baseline and 26 during follow‐up suggesting clinical conversion to MSA‐C. The remaining 248 were classified as SAOA. At baseline, NfL, cerebellar white matter (CWM) and pons volume, and PMAS separated MSA‐C from SAOA. NfL decreased in MSA‐C and did not change in SAOA. CWM and pons volume decreased faster, whereas PMAS increased faster in MSA‐C. In MSA‐C, pons volume had highest sensitivity to change, and PMAS was a predictor of faster progression. Fulfillment of possible MSA criteria, NfL and PMAS were risk factors, CWM and pons volume protective factors for conversion to MSA‐C. Conclusions This study provides detailed information on differential evolution and prognostic relevance of biomarkers in MSA‐C and SAOA. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
dc.languageEN
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleEvolution of Clinical Outcome Measures and Biomarkers in Sporadic Adult-Onset Degenerative Ataxia
dc.title.alternativeENEngelskEnglishEvolution of Clinical Outcome Measures and Biomarkers in Sporadic Adult-Onset Degenerative Ataxia
dc.typeJournal article
dc.creator.authorOender, Demet
dc.creator.authorFaber, Jennifer
dc.creator.authorWilke, Carlo
dc.creator.authorSchaprian, Tamara
dc.creator.authorLakghomi, Asadeh
dc.creator.authorMengel, David
dc.creator.authorSchöls, Ludger
dc.creator.authorTraschütz, Andreas
dc.creator.authorFleszar, Zofia
dc.creator.authorDufke, Claudia
dc.creator.authorVielhaber, Stefan
dc.creator.authorMachts, Judith
dc.creator.authorGiordano, Ilaria
dc.creator.authorGrobe-Einsler, Marcus
dc.creator.authorKlopstock, Thomas
dc.creator.authorStendel, Claudia
dc.creator.authorBoesch, Sylvia
dc.creator.authorNachbauer, Wolfgang
dc.creator.authorTimmann-Braun, Dagmar
dc.creator.authorThieme, Andreas Gustafsson
dc.creator.authorKamm, Christoph
dc.creator.authorDudesek, Ales
dc.creator.authorTallaksen, Chantal Marie Elisabeth
dc.creator.authorWedding, Iselin Marie
dc.creator.authorFilla, Alessandro
dc.creator.authorSchmid, Matthias
dc.creator.authorSynofzik, Matthis
dc.creator.authorKlockgether, Thomas
cristin.unitcode185,53,42,13
cristin.unitnameNevrologisk avdeling
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin2143562
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Movement Disorders&rft.volume=&rft.spage=654&rft.date=2023
dc.identifier.jtitleMovement Disorders
dc.identifier.volume38
dc.identifier.issue4
dc.identifier.startpage654
dc.identifier.endpage664
dc.identifier.doihttps://doi.org/10.1002/mds.29324
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn0885-3185
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial-NoDerivatives 4.0 International
This item's license is: Attribution-NonCommercial-NoDerivatives 4.0 International